New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
09:03 EDTJNJ, ABT, PCYCAbbott collaborates with Janssen and Pharmacyclics for leukemia therapy
Abbott (ABT) announced that it will collaborate with Janssen Biotech (JNJ) and Pharmacyclics (PCYC) to explore the benefits of Abbott's proprietary FISH technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia. Under the agreement, Abbott will develop a FISH-based test to identify high-risk CLL patients who have a deletion within a specific chromosome and may respond to ibrutinib, an oral, small molecule inhibitor of Bruton tyrosine kinase. Ibrutinib is currently in development by Janssen and Pharmacyclics for several B-cell malignancies, including chronic leukemia and lymphoma. Patients harboring a deletion within chromosome 17p are poor responders to chemoimmunotherapy and have limited treatment options. Having a test that is able to accurately detect the 17p deletion identifies a specific patient population with a high unmet medical need.
News For ABT;JNJ;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 20, 2015
07:08 EDTABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
09:59 EDTPCYCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:59 EDTPCYCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
07:41 EDTPCYCPharmacyclics price target raised to $204 from $153 at Leerink
Subscribe for More Information
06:32 EDTPCYCPharmacyclics price target raised to $205 from $180 at Deutsche Bank
Subscribe for More Information
06:24 EDTPCYCPharmacyclics downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:15 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:08 EDTPCYCPharmacyclics upgraded to Buy from Neutral at Nomura
Subscribe for More Information
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
16:06 EDTPCYCPharmacyclics reaffirms 2015 product revenue guidance
Subscribe for More Information
16:04 EDTPCYCPharmacyclics reports Q4 EPS 96c, consensus 76c
Subscribe for More Information
15:35 EDTPCYCNotable companies reporting after market close
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
February 17, 2015
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
09:05 EDTPCYCPharmacyclics announces positive results from treatment with IMBRUVICA
Pharmacyclics announced that treatment with IMBRUVICA was associated with an 88% overall response rate, or ORR, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory, or R/R, high-risk chronic lymphocytic leukemia. These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival, or PFS, at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplant, a procedure in which stem cells from one person are transplanted to another. A second presentation during the BMT Tandem meeting highlighted data from five patients with R/R CLL who had undergone allo-HCT. The researchers concluded that these results support further study of IMBRUVICA in patients following allo-HCT, including those patients with chronic GVHD. Study PCYC 1129, a multicenter open--label Phase Ib/II study of IMBRUVICA in steroid--dependent or refractory chronic GVHD patients, has completed its Phase Ib without dose limiting toxicities and is now enrolling the Phase II portion at the recommended Phase II dose of 420 mg.
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use